简介:Objective:Stromalinteractionmolecule1(STIM1)overexpressionhasbeenreportedtoplayanimportantroleinprogressionofseveralcancers.However,themechanismofSTIM1overexpressionanditsrelationshipwithhypoxiainpancreaticductaladenocarcinoma(PDAC)remainsunclear.Methods:STIM1andHIF-1αexpressionwastestedusingimmunohistochemistryintissuemicroarray(TMA)includingpancreaticcancerandmatchednormalpancreatictissues,andtheirrelationshipswithclinicopathologicalparameterswerestatisticallyanalyzed.q-PCR,Westernblot,ChIP,andluciferaseassaywereemployedto030analyzetranscriptionalregulationbetweenHIF-1αandSTIM1inpancreaticcancerPANC-1cells.Results:BothSTIM1andHIF-1αshowedhigherpositiveratesandup-regulatedexpressionincancertissuescomparedtothatofnormaltissues(P<0.05).TheKaplan–MeiermethodrevealedthathigherHIF-1αandSTIM1expressionlevelsweresignificantlycorrelatedwithdecreaseddisease-freesurvival(P=0.025andP=0.029,respectively).TheexpressionofHIF-1αshowedasignificantpositivecorrelationwiththatofSTIM1incancertissues(rs=0.3343,P=0.0011)andpancreaticcancercelllines.Furthermore,ChIPandluciferaseassaysconfirmedthatHIF-1αboundtotheSTIM1promoterandregulateditsexpressioninPANC-1cells.Conclusions:Inhypoxiamicroenvironment,up-regulatedexpressionofSTIM1mediatedbyHIF-1αpromotesPDACprogression.HIF-1αandSTIM1arepotentialprognosticmarkersand/ortherapeutictargetsforPDACtreatment.
简介:神经纤毛蛋白-1(Neuropilin-1)最早是作为轴突导向分子collapsin/semaphorin的受体被发现,在神经发育过程中引导轴突选择正确途径以成功到达靶区,与此同时又可作为血管内皮生长因子受体-2(VEGFR-2)的共受体表达于血管内皮细胞,在血管新生中发挥作用。近来的研究表明NRP-1可通过依赖于VEGF和独立于VEGF的方式参与调节肿瘤血管新生,在肿瘤生长转移中发挥作用。
简介:目的报道1例胰腺肝样腺癌,探讨血清甲胎蛋白AFP阳性的胰腺肝样腺癌的组织学表现、临床特点及其与预后的关系。方法对1例女性病人的临床资料复查及病理切片行免疫组织化学标记,选用的一抗有AFP、α1-AAT、α1-ACT、CEA、EMA、AE1/AE3、SYN、CgA、NSE、S.100、CD34、PCNA、C-erbB-2,并复习相关文献。结果肿瘤具有2种结构:①具有与肝细胞癌相似的组织学表现,实体状,小梁状,大梁状,血管血窦丰富,免疫组织化学染色AFP弥漫性强阳性,而CEA、EMA灶性阳性,癌细胞为CD34阳性的血管分割成小梁状。②腺癌组织学表现为实体巢状或弥散分布,以及肿瘤性的乳头状上皮、筛状结构,免疫组织化学染色CEA、EMA阳性,而AFP灶性阳性。结论胰腺肝样腺癌具有独特的病理形态和临床特点,是原发性胰腺癌少见的特殊亚型,具有易于复发或转移、预后差的临床特点。
简介:Inrecentyears,furtherunderstandingoftheinteractionbetweentheimmunesystemandtumorgrowthhasledtothedevelopmentofseveralimmunotherapies.Theseimmunotherapiesincludecancervaccinesandimmunecheckpointinhibitorsthathavebeentestedinvarioussolidtumors,includingthosetraditionallyconsiderednon-immunogenic,suchasnon-smallcelllung